RemeGen Co., Ltd. — Earnings Release 2025

Jan 30, 2026

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

RemeGen荣昌生物

RemeGen Co., Ltd.*

荣昌生物製藥（煙台）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

INSIDE INFORMATION ESTIMATED 2025 ANNUAL RESULTS

This announcement is made by RemeGen Co., Ltd.* 荣昌生物製藥(煙台)股份有限公司 (the "Company") pursuant to the disclosure obligations under Rule 13.09(2)(a) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The financial data of the Company for the year of 2025 (the "Period") contained in this announcement has been prepared in accordance with the China Accounting Standards for Business Enterprises and is only preliminary accounting data which has not been audited by an accounting firm. There may be discrepancies between the data contained herein and the final data to be disclosed in the annual report of the Company. Investors are advised to exercise caution when dealing in the shares of the Company.

I. ESTIMATED RESULTS FOR THE PERIOD

(I) Period for Estimated Results

January 1, 2025 – December 31, 2025.

(II) Estimated Results

(1) According to the preliminary estimate made by the finance department of the Company, the operating revenue for the year of 2025 is estimated to be approximately RMB3,250 million, representing an increase of approximately RMB1,533.14 million in revenue as compared with the same period of last year and a year-on-year increase of approximately 89%.

(2) The Company estimates that the net profit attributable to owners of the parent company for the year of 2025 will be approximately RMB716 million, representing a turnaround as compared with the same period of last year.

---

(3) The Company estimates that the net profit attributable to owners of the parent company after deducting the non-recurring gains and losses for the year of 2025 will be approximately RMB78.5 million, representing a turnaround as compared with the same period of last year.

(III) The financial figures relating to the estimated results for the Period have not been pre-audited by certified public accountants.

II. RESULTS FOR THE SAME PERIOD OF LAST YEAR

The operating revenue for the year of 2024 was RMB1,716.8617 million.

The net loss attributable to owners of the parent company for the year of 2024 was RMB1,468.3608 million.

The net loss attributable to owners of the parent company after deducting the non-recurring gains and losses for the year of 2024 was RMB1,507.6424 million.

The loss per share for the year of 2024 was RMB2.73.

III. MAIN REASONS FOR THE CHANGE IN RESULTS FOR THE PERIOD

(I) Impact from Primary Business

During the year of 2025, the sales revenue from the Company's core products, telitacicept and disitamab vedotin increased rapidly in the PRC, becoming the core drivers for business growth. Meanwhile, the Company successfully secured a major collaboration by granting Vor Biopharma Inc the exclusive rights to develop and commercialize telitacicept worldwide (excluding Greater China), leading to a significant increase in technology licensing revenue, with part of overseas R&D investment to be borne by the licensor. In addition, through measures such as management optimization and iterative production process improvements, the Company lowered unit production costs and improved gross profit margins of its products. The sales expense ratio also dropped significantly. Driven by these various positive factors, the Company's profitability efficiency improved substantially, with the expectation of a turnaround in net profit for the year of 2025.

(II) Impact from Non-recurring Gains and Losses

The changes in fair values for warrants obtained from the above licensing-out transaction for the year of 2025 are non-recurring gains. It is expected that the Company's net profit attributable to owners of the parent company after deducting the non-recurring gains and losses will achieve a turnaround for the year of 2025.

IV. RISK WARNING

As at the date of this announcement, there are no material uncertainties that will affect the accuracy of the estimated results for the Period.

---

V. OTHER MATTERS

The figures as mentioned above are only based on preliminary estimates. Please refer to the audited 2025 annual report to be officially disclosed by the Company for accurate financial data. Investors are advised to pay attention to the investment risks.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive director

Yantai, The People’s Republic of China
January 30, 2026

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Wen Qingkai and Mr. Lin Jian as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Mr. Hao Xianjing, Mr. Chen Yunjin and Mr. Huang Guobin as the independent non-executive directors.

• For identification purpose only